Loading clinical trials...
Loading clinical trials...
A Single-dose, Open-label, Randomized, 2-way Cross-over Study of CHF 1535 35/4 NEXThaler® (Fixed Combination of Beclometasone Dipropionate (BDP) 35 μg Plus Formoterol Fumarate (FF) 4 μg Versus the Free Combination of Licensed BDP DPI (Dry Powder Inhaler) and FF DPI in Asthmatic Children
Conditions
Interventions
CHF 1535 35/4µg NEXThaler®
free comb. beclomethasone DPI and formoterol DPI
Locations
1
Denmark
BørneAstmaKlinikken, Hans Knudsens Plads 1A,
Copenhagen, Denmark
Start Date
August 1, 2016
Primary Completion Date
June 1, 2017
Completion Date
June 1, 2017
Last Updated
February 5, 2018
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions